Valuation: PolyPeptide Group AG

Market Cap 1.56B 1.74B 1.45B 1.32B 2.48B 166B 2.5B 17.44B 6.83B 85.77B 6.53B 6.39B 276B P/E 2026 *
58x
P/E 2027 * 30.8x
Enterprise Value 1.66B 1.85B 1.55B 1.4B 2.64B 177B 2.66B 18.57B 7.27B 91.34B 6.96B 6.8B 294B EV / Sales 2026 *
3.3x
EV / Sales 2027 * 2.93x
Free-Float
39.12%
Yield 2026 *
-
Yield 2027 * 0.14%
1 day+0.40%
1 week-0.28%
Current month-0.28%
1 month-0.17%
3 months-4.40%
6 months+46.81%
Current year+69.54%
1 week 43.75
Extreme 43.75
44.15
1 month 43.75
Extreme 43.75
44.8
Current year 23.25
Extreme 23.25
50
1 year 21.95
Extreme 21.9527
50
3 years 13.82
Extreme 13.82
50
5 years 13.82
Extreme 13.82
145.02
10 years 13.82
Extreme 13.82
145.02
Manager TitleAgeSince
Chief Executive Officer 54 2023-04-11
Director of Finance/CFO 54 2024-01-01
Chief Tech/Sci/R&D Officer 54 -
Director TitleAgeSince
Director/Board Member 73 2005-12-31
Chairman 69 2021-03-31
Director/Board Member 62 2020-12-31
Change 5-day change 1-year change 3-year change Capi.($)
+0.40%-0.28% - - 1.74B
+0.28%+3.46%+41.89%+93.71% 1,051B
+0.88%+4.27%+38.28%+68.70% 630B
+1.68%+5.78%+21.96%+89.56% 489B
-0.10%+4.24%+69.15%+40.41% 359B
+0.61%+3.18%+24.05%+42.46% 344B
+0.72%+2.99%+14.29%+34.71% 272B
+0.23%+2.23%-5.91%+8.15% 246B
+0.65%+3.62%+43.93%+46.50% 224B
-0.49%+4.01%+28.38%+95.97% 187B
Average +0.43%+3.11%+30.67%+57.80% 422.63B
Weighted average by Cap. +0.41%+3.18%+34.07%+66.93%

Financials

2026 *2027 *
Net sales 502M 561M 468M 424M 800M 53.6B 805M 5.62B 2.2B 27.66B 2.11B 2.06B 89B 576M 643M 537M 487M 919M 61.51B 924M 6.45B 2.53B 31.74B 2.42B 2.36B 102B
Net income 23.5M 26.26M 21.91M 19.87M 37.49M 2.51B 37.72M 263M 103M 1.3B 98.63M 96.45M 4.17B 45.23M 50.52M 42.16M 38.24M 72.13M 4.83B 72.58M 507M 198M 2.49B 190M 186M 8.02B
Net Debt 101M 113M 94.11M 85.36M 161M 10.78B 162M 1.13B 443M 5.56B 424M 414M 17.9B 131M 146M 122M 111M 209M 13.98B 210M 1.47B 574M 7.21B 549M 537M 23.21B
Projected Income Statement - Annual - PolyPeptide Group AG
Logo PolyPeptide Group AG
Polypeptide Group AG is a Switzerland-based Contract Development & Manufacturing Organization (CDMO) focusing on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development as well as in generic products.
Employees
1,460
Date Price Change Volume
26-10-12 CHF 44.00 -0.11% 2
26-10-09 CHF 44.05 +0.46% 2,005
26-10-08 CHF 43.85 -0.23% 907
26-10-07 CHF 43.95 -0.23% 1,180
26-10-06 CHF 44.05 -0.11% 404
Trader
Investor
Global
Quality
ESG MSCI
A
Ratings Surperformance© - PolyPeptide Group AG
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
47.15EUR
Average target price
45.99EUR
Spread / Average Target
-2.46%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - PolyPeptide Group AG